Coherus Management to Present at the 44th Annual J.P. Morgan Healthcare Conference
Coherus Oncology (NASDAQ: CHRS) said senior management will present at the 44th Annual J.P.
Rhea-AI Summary
Coherus Oncology (NASDAQ: CHRS) said senior management will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026 at 10:30 a.m. PT.
The presentation and Q&A will stream via webcast and a link will be posted on the company's Investor Events Calendar at https://investors.coherus.com/events-presentations. The webcast replay will be available through February 13, 2026.
Positive
- None.
Negative
- None.
Details
News Market Reaction – CHRS
In the Jan 6 session, CHRS declined 5.56%, reflecting a notable negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
- Current price
- $1.44
- Prior to conference news on Jan 06, 2026
- Daily price change
- 5.11%
- Pre-news 24h price move
- Today’s volume
- 2,648,401 shares
- Versus 20-day average volume of 968,716 shares
- 52-week range
- $0.71 – $1.89
- Price sits 23.81% below 52-week high
- Shelf capacity
- $150.0 million
- Maximum mixed securities under Form S-3 filed Nov 13, 2025
- Conference time
- 10:30 a.m. Pacific Time
- J.P. Morgan Healthcare Conference presentation on Jan 13, 2026
- Webcast replay window
- Until Feb 13, 2026
- Replay availability for J.P. Morgan presentation webcast
Historical Context
-
Reported six-year JUPITER-02 data showing markedly improved overall survival with LOQTORZI.
-
Presented detailed CHS-114 biomarker and safety data in HNSCC at SITC 2025.
-
Released Q3 2025 results showing LOQTORZI-driven revenue growth but continued net loss.
-
Announced new Chief Strategy and Corporate Affairs Officer to support oncology focus.
-
Set date and webcast details for upcoming Q3 2025 financial results announcement.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
REDWOOD CITY, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS) today announced that senior management will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 10:30 a.m. Pacific Time. The presentation and Q&A session will be accessible via webcast through a link posted on the Investor Events Calendar section of the Coherus website: https://investors.coherus.com/events-presentations.
This webcast will be available for replay until February 13, 2026.
About Coherus Oncology
Coherus Oncology is a fully integrated commercial-stage innovative oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI® (toripalimab-tpzi), and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, colorectal and other cancers. The Company’s strategy is to grow sales of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as through its partners, driving sales multiples and synergies from proprietary combinations.
Coherus’ innovative oncology pipeline includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust antitumor response and enhance outcomes for patients with cancer. Tagmokitug is a highly selective cytolytic anti-CCR8 antibody currently in Phase 1b/2a studies in patients with advanced solid tumors, including head and neck squamous cell carcinoma, colorectal cancer, gastric cancer, and esophageal cancer. Casdozokitug is a novel IL-27 antagonistic antibody currently being evaluated in a Phase 2 study in patients with first-line hepatocellular carcinoma.
For more information about LOQTORZI, including the U.S. Prescribing Information and important safety information, please visit www.loqtorzi.com.
LOQTORZI® is a registered trademark of Coherus Oncology, Inc.
©2026 Coherus Oncology, Inc. All rights reserved.
Coherus Oncology Contact Information:
For Investors:
Carrie Graham
VP, Investor Relations & Advocacy
IR@coherus.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.